Table 3.
Medical treatment and outcome of treatment between patients with CMV-positive and CMV-negative Posner-Schlossman syndrome
| Characteristics | CMV-Negative Patients (N = 22) |
CMV-Positive Patients (N = 25) |
P Valuea |
|---|---|---|---|
| Medical treatment at the first visit | |||
| Number of patients treated with antiglaucoma medication | 20 (90.9) | 15 (60) | .015* |
| Number of antiglaucoma agents used simultaneously | 2.0 (1.5–2.4) | 1.0 (0.6–1.5) | .005* |
| Frequency of corticosteroid eye drop (times per day) | 2.5 (2.1–2.9) | 2.8 (2.5–3.1) | .271 |
| Number of patients with corticosteroid dependency | 13 (59.1) | 12 (48) | .447 |
| Ocular outcomes at the end of follow-up | |||
| IOP (mm Hg) | 16.7 (15.0–18.3) | 14.4 (13.2–15.7) | .016* |
| IOP reduction (mm Hg) (compared with the IOP at the first clinic visit) | 13.0 (7.8–18.1) | 14.6 (10.4–18.8) | .129 |
| mutton-fat KPs | 9 (40.9) | 15 (60) | .191 |
| Coin-shaped KPs | 1 (4.5) | 0 (0) | .281 |
| Tyndall effect | 0 (0) | 0 (0) | NA |
| Medical treatment at the end of follow-up | |||
| Number of patients treated with antiglaucoma medication | 11 (50) | 8 (32) | .210 |
| Number of antiglaucoma agents used simultaneously | 1.0 (0.5–1.5) | 0.5 (0.2–0.9) | .148 |
| Frequency of corticosteroid eye drop (times per day) | 0.5 (0.2–0.9) | 1.0 (0.5–1.4) | .213 |
| Duration of follow-up (weeks) | 4.9 (3.8–6.0) | 5.9 (4.7–7.2) | .202 |
Data are expressed as mean (95% C.I) or number of patients (%)
IOP intraocular pressure, KPs keratic precipitates, NA not applicable
aχ2 test or Fisher’s exact test was used to compare proportions between CMV-negative and CMV-positive PSS; Mann-Whitney U test was used to compare continuous variables between CMV-negative and CMV-positive PSS
*p < .05